Kohlberg Kravis Roberts & Co. L.P. CHRS COHERUS BIOSCIENCES INC

Ownership history in Kohlberg Kravis Roberts & Co. L.P.  ·  40 quarters on record

AI Ownership Summary

Kohlberg Kravis Roberts & Co. L.P. reported COHERUS BIOSCIENCES INC (CHRS) in 40 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 0.3% in 2023 Q4. The latest visible filing shows CHRS at 0.07% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CHRS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Kohlberg Kravis Roberts & Co. L.P.'s position in COHERUS BIOSCIENCES INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

CHRS was reported at 0.07% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.3% in 2023 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Kohlberg Kravis Roberts & Co. L.P. held CHRS — position size vs. price
% of Fund (quarterly)    CHRS price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 9 quarters  
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 UNCHANGED 3,036,076 0% 0.07% $4.2M 2026-02-14 (Est.) $1.61
2025 Q3 UNCHANGED 3,036,076 0% 0.08% $4.93B 2025-11-14 $1.19
2025 Q2 UNCHANGED 3,036,076 0% 0.04% $2.17B 2025-08-14 $1.02
2025 Q1 UNCHANGED 3,036,076 0% 0.05% $2.41B 2025-05-15 $0.77
2024 Q4 UNCHANGED 3,036,076 0% 0.11% $4.15B 2025-02-14 $1.18
2024 Q3 UNCHANGED 3,036,076 0% 0.04% $3.12B 2024-11-14 $0.77
2024 Q2 UNCHANGED 3,036,076 0% 0.16% $5.25B 2024-08-14 $1.37
2024 Q1 UNCHANGED 3,036,076 0% 0.19% $7.26B 2024-05-15 $2.18
2023 Q4 UNCHANGED 3,036,076 0% 0.30% $10.11B 2024-02-14 $2.72
31 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

FAQ About Kohlberg Kravis Roberts & Co. L.P. and CHRS

These are the practical questions this page is built to answer before you even open the full history table.

How long has Kohlberg Kravis Roberts & Co. L.P. reported owning CHRS?

Kohlberg Kravis Roberts & Co. L.P. reported CHRS across 9 quarterly 13F filings, from 2023 Q4 through 2025 Q4.

What was the largest reported CHRS position in Kohlberg Kravis Roberts & Co. L.P.'s portfolio?

The largest reported portfolio weight for CHRS was 0.30% in 2023 Q4.

What is the latest reported CHRS position on this page?

The most recent filing on this page is 2025 Q4, when Kohlberg Kravis Roberts & Co. L.P. reported 3,036,076 shares, equal to 0.07% of portfolio, with an estimated market value of $4.2M.

What does the chart on this CHRS ownership page compare?

The chart compares Kohlberg Kravis Roberts & Co. L.P.'s quarterly CHRS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Kohlberg Kravis Roberts & Co. L.P. Holdings